# First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/first-line-icotinib-versus-cisplatin-pemetrexed-plus-pemetrexed-maintenance/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yuankai Shi,L. Wang,Baohui Han,W. Li,Pei-wu Yu,Y.P. Liu,Chunming Ding,Xia Song,Z.Y. Ma,Xiaowen Ren,J. Feng,H. L. Zhang,G. -Y. Chen,Xiaohong Han,Ning Wu,Chia-Yu Yao,Yong Song,S. C. Zhang,Wei Song,X. Q. Liu,Sha Zhao,Yangxuan Lin,X.Q. Ye,K. Li,Yongqian Shu,Lili Ding,F. Tan,Yan Sun |
| Citations | 342 |
| DOI | 10.1093/annonc/mdx359 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2747505649 |
| PMID | 28945850 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Baohui Han](https://scholariq.org/researchers/baohui-han/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.